A Study to Investigate the Efficacy, Safety and Tolerability of PEG in Patients With Genital Herpes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01765114
Recruitment Status : Terminated (insufficient patient recruitment)
First Posted : January 10, 2013
Last Update Posted : August 5, 2014
Information provided by (Responsible Party):
Devirex AG

Brief Summary:
The aim of this study is therefore to investigate the efficacy of the PEG-formulation to reduce the frequency and duration of genital herpes recurrences, to assess its safety and tolerability and to investigate its effect on shedding.

Condition or disease Intervention/treatment Phase
Genital Herpes Drug: PEG-Formulation Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Open-label, Intra-individual Controlled, Single-center Study to Investigate the Efficacy, Safety and Tolerability of a Polyethylene Glycol-formulation and the Viral Shedding in Patients Suffering From Genital Herpes
Study Start Date : February 2013
Actual Primary Completion Date : August 2014
Actual Study Completion Date : August 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Genital Herpes

Arm Intervention/treatment
Experimental: PEG-Formulation
PEG-Formulation, applied twice daily during the treatment period (duration: 6 months)
Drug: PEG-Formulation

Primary Outcome Measures :
  1. Change of number of genital herpes recurrences during the treatment period as compared to the baseline period. [ Time Frame: Baseline and Treatment period (6 months each). ]
    The number of genital herpes recurrences will be counted during the baseline period (6 months) and during the treatment period (6 months) and then be compared.

Secondary Outcome Measures :
  1. The safety of the PEG-formulation via reporting of AEs. [ Time Frame: Baseline and Treatment period (6 months each). ]

Other Outcome Measures:
  1. The frequency of days with viral shedding which will be analysed by quantitative PCR. [ Time Frame: Baseline and Treatment period (6 months each). ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Informed Consent
  • 18 - 65 years
  • Positive for HSV-1 and/or -2 (as determined by serology testing in course of study)
  • Initial infection > 1 year ago
  • ≥ 6 recurrences in the last year (or in the year prior to a recent prophylactic therapy)
  • ≥ 2 recurrences during the six-month baseline period

Exclusion Criteria:

  • Known or suspected allergy or intolerability to PEG
  • Prophylactic antiviral drugs, virostatic agents, cytostatics, immunomodulatory drugs and steroids within less than 14 days prior to baseline period, or plan to take such drugs during the trial
  • Pregnancy and/or breast-feeding
  • History of malignant diseases (described in chapter 7.2)
  • Known or suspected non-compliance to study protocol
  • Participation in another investigational drug study in the last 30 days prior to baseline period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01765114

University Hospital Zurich
Zurich, Switzerland, 8091
Sponsors and Collaborators
Devirex AG
Principal Investigator: Thomas Kuendig, MD University of Zurich

Responsible Party: Devirex AG Identifier: NCT01765114     History of Changes
Other Study ID Numbers: DEV-PEG-02
First Posted: January 10, 2013    Key Record Dates
Last Update Posted: August 5, 2014
Last Verified: August 2014

Additional relevant MeSH terms:
Herpes Genitalis
Herpes Simplex
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Genital Diseases, Male
Genital Diseases, Female